Burosumab Injection [Crysvita]
RxNorm 2043862

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2043862 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: burosumab Injection [Crysvita].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDF
Burosumab Injection [Crysvita]
AUI:10268910
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDFPrescribable

Semantic Branded Drug Form (SBDF):
Burosumab Injection [Crysvita]
(Atom ID: 10268910)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
burosumab Injection [Crysvita]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2043862
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10268910
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDF
Semantic Branded Drug Form (Ingredient + Dose Form + Brand Name)
Source Code
2043862
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Burosumab-twza Injection


Burosumab-twza injection is used to treat X-linked hypophosphatemia (XLH; an inherited disease where the body doesn't maintain phosphorus and that leads to weak bones) in adults and children 6 months of age and older. It is also used to treat tumor-induced osteomalacia (a tumor that causes a loss of phosphorus in the body that leads to weak bones) that cannot be surgically removed in adults and children 2 years of age and older, Burosumab-twza injection is in a class of medications called fibroblast growth factor 23 (FGF23) blocking antibodies. It works by blocking the action of a certain natural substance in the body which causes the symptoms of XLH.
[Learn More]


* Please review the disclaimer below.